GPC3 and hepatocellular carcinoma: A recent phase I clinical trial investigating IL-15-enhanced GPC3-targeting CAR-T cells for the treatment of HCC demonstrated their antitumor capacity but also raised safety concerns due to an increased incidence of CRS104.